Lyda M. Osorio
Corporate Officer/Principal presso IMED AB
Profilo
Lyda M.
Osorio is currently the Head-Pharmacology at IMED AB.
Prior to this, she worked as a Principal at Karolinska Institutet.
Posizioni attive di Lyda M. Osorio
| Società | Posizione | Inizio |
|---|---|---|
IMED AB
 IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Corporate Officer/Principal | 26/11/2009 |
Precedenti posizioni note di Lyda M. Osorio
| Società | Posizione | Fine |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
- Borsa valori
- Insiders
- Lyda M. Osorio
